SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being discussed alongside concerns about its heavy debt load, rising borrowing costs and whether AI demand and contract backlog can support its financing needs, with HSBCs bearish assessment adding to the pressure. Traders are split between viewing the balance-sheet risks and insider selling as reasons for further downside and arguing that strong demand, the backlog and Nvidia ties make the drop a buying opportunity.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling a heavily bearish conversation, with traders tying its political-proxy appeal to concerns about Trumps approval and the midterms, while questioning the companys business traction. A smaller bullish contingent sees a possible trading bounce and points to the pending TAE fusion deal as a potential pivot.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound toward a one-year high and the $30 level is driving discussion, with traders focused on whether the move can break through resistance. Some see momentum from a defensive-sector rotation and pipeline developments ahead of earnings, while others say the stock needs stronger news to sustain a breakout.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp selloff across AI infrastructure and neocloud stocks as investors question whether heavy data-center spending and financing risks will generate adequate returns, with Gartners warning adding to the concern. Traders disagree on whether the pressure signals more downside or an oversold opportunity, with bulls pointing to IRENs contracted demand, power assets, and managements financing reassurances.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention for a sharp rebound after a tech-led selloff, which traders link to unconfirmed reports of potential U.S.-Iran talks and easing oil prices. The community is split between viewing the move as a bullish reversal and warning it may be a bull trap amid persistent volatility and concerns about tech and AI stocks.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A semiconductor rebound after a prolonged selloff is driving attention, with traders debating whether the move signals a durable bottom or a temporary bounce amid lingering concerns about AI spending and valuations. Chip gains are part of a broader technology recovery ahead of major tech earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why

Longeveron shares fell 59% after hours after its ELPIS II trial missed its primary endpoint.read more...

Longeveron (LGVN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Longeveron CFO Lisa Locklear To Step Down; Marie Washburn Appointed As Successor

(RTTNews) - Longeveron Inc. (LGVN) on Monday announced that Chief Financial Officer Lisa Locklear is stepping down to pursue board opportunities and other professional and personal interests. The company appointed Marie Washburn as Senior Vice President and CFO, effective July 13...

LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design

Equity

Though the firm called the meeting ‘constructive’, investors seem more focused on the agency’s reservations about the laromestrocel trial’s design and its potential to support approval.

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells Biotechs Racing to...

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. PR...

Longeveron (LGVN) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Longeveron Braces For Q4 Results Following Recent Funding Boost

Longeveron Inc. shares are trading higher Tuesday as investors pivot their focus toward the company's Q4 earnings report, due after the bell.read more...

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Longeveron shares are trading sharply higher Tuesday afternoon following the announcement of a private placement agreement worth up to $30 million.read more...

Best Biotech Stocks To Keep An Eye On - March 10th

Vertex Pharmaceuticals, BioNTech, Danaher, Longeveron, Moderna, United Therapeutics, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Longeveron Inc - Ordinary Shares - Class A

Neutral Sentiment

<ul class="summary-bullets"><li>The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.”</li><li>As a result, the FDA no longer considers the study to be “pivotal.”</li><li>Top-line data from the 40-patient randomized, controlled study are still expected in August 2026.</li></ul> Longeveron Inc. (LGVN) shares fell 4% in after-hours trading on Friday after the U.S. Food and Drug Administration expressed reservations on the trial design for its cell therapy laromestrocel.Longeveron announced that it held a meeting with the FDA in late March 2026 to discuss the ongoing mid-stage trial of its investigational cell therapy laromestrocel in infants with hypoplastic left heart syndrome (HLHS), a severe, rare congenital heart defect where the left side of a baby's heart is severely underdeveloped and cannot properly pump blood to the body. Though the firm called the meeting ‘constructive’, investors seem more focused on the agency’s reservations about the trial’s design and its potential to support approval.<h2 class="st-heading-2">Meeting Outcomes</h2>The FDA acknowledged that HLHS is a rare, life-threatening congenital heart defect with “significant morbidity and mortality” and a high unmet medical need. However, the agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.”Longeveron said it agreed with the FDA’s assessment that the endpoint alone is insufficient. Though the company had hoped to discuss alternative or composite endpoints, the FDA indicated it could not agree to a new primary endpoint while the trial is still ongoing, it said.As a result, the FDA no longer considers the study to be “pivotal” — a designation the agency had previously discussed with the company.The release noted that the FDA is “willing to meet with Longeveron again when the ongoing ELPIS II study is completed to discuss the study results and align on a potential path forward.” Top-line data from the 40-patient randomized, controlled study are still expected in August 2026The agency emphasized that only the most objective clinical measures — all-cause mortality, cardiac transplant-free survival, events of cardiac transplantation, and well-defined major adverse cardiac events (MACE) — would be considered informative for efficacy. Longeveron said it is already capturing those endpoints, along with additional supportive measures.The company plans to submit a revised plan featuring a composite primary endpoint and secondary endpoints for FDA review. It remains “optimistic” that the full dataset, combined with other evidence, will still support an application filing after the August readout.<h2 class="st-heading-2">How Did LGVN Retail Traders React?</h2>On Stocktwits, retail sentiment around LGVN stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.A Stocktwits user said that they will take their loss with the company.<stembedurl>https://www.stocktwits.com/Dorps332/message/652803025</stembedurl>Another highlighted the negative takeaways from the meeting.<stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/652802598</stembedurl><a href="https://stocktwits.com/symbol/LGVN">LGVN stock</a> has fallen 43% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-clocks-best-day-in-over-two-months-on-early-stage-hantavirus-vaccine-research/cZX2zB5Rego">MRNA Stock Clocks Best Day In Over Two Months On Early-Stage Hantavirus Vaccine Research</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Longeveron, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on January 3, 2025. (Photo Illustration by Jaque Silva/NurPhoto via Getty Images)

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$1.39
Prev Close	$1.39
Open	$1.40
Dividend Yield	0.00%
50-Day Moving Average	$4.98
Beta	0.92
Avg. Volume	174,189.11
PE Ratio	-0.14

52-Week High	$12.30
52-Week Low	$1.31
Market Capitalization	$4.43M
EPS (Annual)	-$12.92
Price to Book	0.42
Revenue Per Employee	$31,552.63

Feed

News

Sentiment

Earnings

Fundamentals

Info

LGVN Fundamentals